Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Cytrx to commence Phase 2 trial of bafetinib for advanced prostate cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced plans to initiate a Phase 2 proof-of-concept clinical trial in the second half of 2010 to evaluate the effectiveness and safety of its oncology drug candidate bafetinib (formerly known as INNO-406) in patients with an advanced form of prostate cancer known as metastatic hormone-refractory prostate cancer.

7 Apr 2010

Updated report analyzing approval rates at FDA published

Sagient Research Systems, a leading publisher of independent research for the financial services, institutional investment and corporate intelligence communities, recently published an updated report analyzing approval rates at the U.S Food and Drug Administration. According to its research service, BioMedTracker, the rate of drugs that were approved by the FDA in 2008 and 2009 has remained close to the historical low seen in 2007.

7 Apr 2010

Prostate cancer testing: Doctors should warn men of possible distress

Doctors should warn men that prostate cancer testing may lead to anxiety and distress, say Cancer Research UK experts.

7 Apr 2010

Emory University researchers develop experimental clinical test for XMRV

The recently discovered retrovirus, xenotropic murine leukemia virus-related virus (XMRV), has been identified in some prostate cancer patients. In light of conflicting data concerning XMRV, standardized diagnostic testing is important to identify patients in which XMRV is present and to determine whether it plays a role in the incidence of prostate cancer.

6 Apr 2010

Cancer research at Georgia Tech: Report

Cancer treatment typically involves surgery, radiation therapy, chemotherapy, hormone therapy or biological therapy. An oncologist may use one therapy or a combination of methods, depending on the type and location of the cancer, whether the disease has spread, the patient's age and general health, and other factors.

3 Apr 2010

Study could aid in developing new, effective treatments for prostate cancer

Van Andel Research Institute (VARI) scientists have determined how two proteins required for the initiation and development of prostate cancer interact at the molecular level, which could lead to improved treatments for the disease.

3 Apr 2010

Cancer Prevention Coalition submits petition on imminent health hazard from hormonal meat

As reported in a March 18, New York Times editorial, "Honest Food Labels," FDA Commissioner, Margaret Hamburg, M.D., publicized letters to 17 food companies accusing them of -- "masking undesirable ingredients" -- in their products. She also emphasized the importance of "providing nutrition information that consumers can rely on."

3 Apr 2010

2010 Internal Medicine conference at Toronto Convention Center

More than 5,000 internists (adult medicine specialists), subspecialists, medical students, and allied health professionals will meet in Toronto, Canada, for Internal Medicine 2010, the annual scientific meeting of the American College of Physicians (ACP), April 22 - 24 (Thursday - Saturday), at the Toronto Convention Center.

2 Apr 2010

International, four-year study finds dutasteride reduces risk of prostate cancer diagnosis in men

A drug already prescribed to shrink benign, enlarged prostates has been shown to reduce the risk of a prostate cancer diagnosis by 23 percent in men with an increased risk of the disease, a large international trial has found. Results are reported April 1 in the New England Journal of Medicine.

2 Apr 2010

Soligenix's revenues for 2009 increase by 22%

Soligenix, Inc., a late-stage biopharmaceutical company, today announced its financial results for 2009.

1 Apr 2010

Refinements to CTC-chip may better monitor how CTC levels react to prostate cancer treatment

Technical improvements to a microchip-based device for detecting and analyzing tumor cells in the bloodstream are revealing cellular differences that may reflect a tumor's aggressiveness and long-term response to treatment.

1 Apr 2010

Dutasteride reduces risk of prostate cancer

There is good news for those at high risk for prostate cancer. The drug dutasteride which is manufactured by GlaxoSmithKline as the drug Avodart, has been found to reduce the risk of prostate cancer by a quarter. The drug is at present being used to treat enlarged prostates.

1 Apr 2010

New medicines to fight diseases of particular concern to African Americans

A recent article in The Triangle Tribune pointed to good news for members of the black community, highlighting new medicines in development to fight diseases of particular concern to African Americans.

1 Apr 2010

Nymox Pharmaceutical's NX-1207 human clinical trials for HCC demonstrate favorable safety data

Nymox Pharmaceutical Corporation outlined today the Company's development program for the Company's lead drug candidate, NX-1207, currently in Phase 3 trials in the U.S. for the treatment of benign prostatic hyperplasia (BPH). The drug has been successful in a series of blinded controlled multi-center U.S. clinical trials where it has been found to produce improvements that are about double that reported for currently approved BPH drugs.

31 Mar 2010

Virginia Tech professor receives NSF CAREER award for research on cancer therapies using nanotechnology

Preliminary research on cancer treatments using nanotechnology and laser therapy has led to a National Science Foundation (NSF) Faculty Early Career Development (CAREER) award for Marissa Nichole Rylander, Virginia Tech assistant professor jointly appointed in the Department of Mechanical Engineering and Virginia Tech - Wake Forest University School of Biomedical Engineering and Sciences (SBES).

30 Mar 2010

'Because Life is for Living' campaign launched to raise awareness about brachytherapy

Former England Rugby World Cup winner Matt Dawson today launched the 'Because Life is for Living' campaign to raise awareness about brachytherapy, a very precise and highly effective form of radiotherapy to treat cancer.

30 Mar 2010

U.Va. develops Prostate Exam Simulator

Early detection through physical examination is one of the key factors in successfully treating prostate cancer.

30 Mar 2010

GSK re-submits sNDA for Avodart to FDA

GlaxoSmithKline announced today that it has re-submitted the supplemental New Drug Application for Avodart® (dutasteride) for prostate cancer risk reduction among men at increased risk of developing the disease to the US Food and Drug Administration.

30 Mar 2010

Inovio Biomedical's total revenue increased to $2.6M for quarter ended December 31, 2009

Inovio Biomedical Corporation today reported financial results for the quarter and year ended December 31, 2009.

29 Mar 2010

Agent Orange exposure: VA adds three new illnesses to list of health problems

Well over 100,000 Veterans exposed to herbicides while serving in Vietnam and other areas will have an easier path to qualify for disability pay under a proposed regulation published by the Department of Veterans Affairs (VA) that adds three new illnesses to the list of health problems found to be related to Agent Orange and other herbicide exposures.

27 Mar 2010